Ten challenges for TB biomarkers
Ten challenges for TB biomarkers
复制标题
DOI：
10.1016/s1472-9792(12)70007-0
复制
发表时间：
2012-03-01
期刊：
影响因子：
3.2
通讯作者：
Kaufmann, Stefan H. E.
中科院分区：
文献类型：
--
作者：
Ottenhoff, Tom H. M.;Ellner, Jerrold J.;Kaufmann, Stefan H. E.
结核病（TB）生物标志物的保护（或：“预防活动性TB的替代终点”（生物标志物定义工作组，2001年））的可用性将大大促进和加速TB疫苗的开发，并增加成功的可能性。结核病保护生物标志物可以确定临床试验中的哪种疫苗最有效;哪种候选疫苗和策略在临床前开发管道的早期阶段最有希望（包括相关抗原、抗原递送、活疫苗）;以及哪种组合疫苗（初免/加强）最有效。在这里，我们讨论了结核病生物标志物鉴定和验证的十大挑战。目前的主要障碍和关键的限制，了解结核病的发病机制，并提出了新的解决方案和战略。(C)2012爱思唯尔有限公司保留所有权利。
The availability of tuberculosis (TB) biomarkers of protection (or: "surrogate endpoints of protection against active TB" (Biomarkers Definitions Working Group, 2001)) would greatly facilitate and accelerate TB vaccine development and increase the likelihood of success. TB biomarkers of protection could determine which vaccines in clinical trials are the most efficacious; which vaccine candidates and strategies are the most promising in early stages in the preclinical development pipeline (including relevant antigens, antigen delivery, live vaccines); and which combination vaccines (prime/boost) would be the most effective. Here we discuss ten major challenges for biomarker identification and validation in TB. Current major roadblocks and critical limitations in understanding TB pathogenesis are highlighted, and new solutions and strategies proposed. (C) 2012 Elsevier Ltd. All rights reserved.